HOME > COMMENTARY
COMMENTARY
-
Japanese Drug Makers Working to Increase Pace of Drug Discovery by Optimizing Operations at Research Centers
August 18, 2014
-
PMDA Sets Target Review Times for Partial Changes to Generic Approval - A New Way to Underpin Stable Supply
August 4, 2014
-
Competition Fuels Personalized Medicine Market, First-Line Positions Eyed for Xalkori, Alecensa
July 28, 2014
-
Can New Fast-Track Review System Perk Up Drug Makers’ Development Drive in Japan?
July 7, 2014
-
June Reimbursement Listing Could Mark Watershed in Japan Generic Market
July 1, 2014
-
Two Reasons MHLW Opposes Yearly NHI Price Revisions, “Annual” Dropped from Gov’t Policy Guidelines
June 17, 2014
-
Delicate Balancing Act Required for SGLT-2 Inhibitor Promotions - Safety vs Efficacy
June 16, 2014
-
Why Not Make RMPs for Existing Products as Differentiation Strategy?
June 9, 2014
-
2013 Earnings Signal Foreign Drug Makers Losing Steam in Japan
June 2, 2014
-
Clinical Research Regulations at Crossroads: Guidelines or Legislation?
May 26, 2014
-
Was the Main Paper from VART Study “Practice” for a Grad Student?
May 19, 2014
-
Can CROs Become Independent Players? Compliance, Ethics Will Be Major Issues for Growing Industry
April 28, 2014
-
Industry Faces Tough Road to Institutionalization of Key Premium, Eligibility Up for Discussion
April 21, 2014
-
Approval of Novel Antiepileptic Drugs as Monotherapies Coming Closer to Reality
April 7, 2014
-
Will Japan NIH Initiative Create a “Japanese Model” that Overcomes Its Size Disadvantage?
March 28, 2014
-
CASE-J Flutter: Doesn’t Blopress Ad Overemphasize Its Benefits on Diabetes?
March 19, 2014
-
“Lack of Urgency” Leads to New Rule; Penalty for Low Price Settlement Rates May Have Been Inevitable
March 12, 2014
-
Hardships and Successes of Diversified Entrants Lead to Question: Will Pharmaceuticals Continue to Be a Growth Sector?
March 5, 2014
-
Revised JCS Guidelines Clarify Role of Novel Oral Anticoagulants in Patients with Atrial Fibrillation
February 12, 2014
-
Will JPWA’s Move to Integrate Tax Display Method Dispel Medical Institutions’ Misconception?
January 31, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
